Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
- PMID: 34826380
- PMCID: PMC8610424
- DOI: 10.1016/S1473-3099(21)00687-3
Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
Conflict of interest statement
We declare no competing interests.
Comment on
-
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23. Lancet Infect Dis. 2022. PMID: 34826381 Free PMC article. Clinical Trial.
References
-
- Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00677-0. published online Nov 23. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous